|Year : 2019 | Volume
| Issue : 4 | Page : 348-349
MCQs on “Analysis of postoperative radiotherapy effects within risk groups in patients with FIGO I, II, and III endometrial cancer”
HS Darling1, S Jayalakshmi2, Pradeep Jaiswal3
1 Department of Medical Oncology and Hemato-Oncology, Narayana Superspeciality Hospital, Gurugram, Haryana, India
2 Department of Radiation Oncology, Artemis Hospital, Gurugram, Haryana, India
3 Department of Surgical Oncology, Command Hospital, Bangalore, Karnataka, India
|Date of Web Publication||11-Oct-2019|
H S Darling
Department of Medical Oncology and Hemato-Oncology, Narayana Superspeciality Hospital, Gurugram, Haryana
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Darling H S, Jayalakshmi S, Jaiswal P. MCQs on “Analysis of postoperative radiotherapy effects within risk groups in patients with FIGO I, II, and III endometrial cancer”. Indian J Cancer 2019;56:348-9
|How to cite this URL:|
Darling H S, Jayalakshmi S, Jaiswal P. MCQs on “Analysis of postoperative radiotherapy effects within risk groups in patients with FIGO I, II, and III endometrial cancer”. Indian J Cancer [serial online] 2019 [cited 2020 Aug 7];56:348-9. Available from: http://www.indianjcancer.com/text.asp?2019/56/4/348/268966
1: Risk factors for endometrial cancer are all except
(a) Age >60 years
(d) Early menarche, late menopause
2: At the time of diagnosis, what percentage of patients has FIGO stage IV B?
3: In the present study, which factor was not significantly associated with time to progression?
(a) Adjuvant radiotherapy
(b) Number of deliveries
(c) FIGO stage
4: The role of adjuvant chemotherapy in this study was
(a) Increased PFS but no OS
(b) Increased PFS as well as OS
(c) There was no impact on survival
(d) Chemotherapy was not used in this study
5: Maximum percentage of patients was from which risk group?
(a) Low risk
(b) Moderate risk
(c) Medium risk
(d) High risk
6: Major limitations of this study were all except
(a) Single center study
(b) Small sample size
(c) Elderly population
(d) Toxicities were nor reported
7: Median OS in this study was
(a) 80 months
(b) 41.5 months
(c) 52 months
(d) 21.5 months
8: Most common family history was
(c) Cardiac disease
(d) Kidney disease
9: Maximum overall survival according to localization of distant metastases was found in patients with
(a) Lung only metastases
(b) Liver only metastases
(c) Simultaneous liver and bone metastases
(d) Bone only metastases
10: The incorrect statement about radiotherapy (RT) modality used is
(a) The smallest number of patients received transcutaneous RT
(b) Maximum patients received intracavitary brachytherapy
(c) These details are not available
(d) Maximum patients received transcutaneous RT plus intracavitary brachytherapy
Answers and explanations
Risk factors for endometrial cancer are age (over 60 years), obesity, diabetes, hypertension, hyperthyroidism, early menarche, and late menopause, larger number and longer duration of menstrual cycles, multiparity, infertility, irregular menstrual cycles due to lack of ovulation, presence of hormone-dependent breast cancer, and other.
At the time of diagnosis, about 8% of patients have distant metastases.
Comorbidities (P = 0.033), FIGO stage (P = 0.000), metastases localization (P = 0.039), adjuvant radiotherapy (P = 0.031), and late toxicity organ site (P = 0.013) had significant influence on time to progression.
The exclusion criteria were unknown stage/grade, systemic chemotherapy application, previous pelvic radiotherapy, and radiotherapy initiated more than 7 weeks after surgery.
[Table 2], Low risk 18 (22.5%), moderate risk 31 (37.5%), medium risk 23 (28.8%), high risk 9 (11.3%).
Limitations of our study were that the study was conducted in a single center and on a small sample of patients. In addition, majority of patients were older than age 65 years.
OS for a 5-year period was 80%, whereas the median OS was 41.5 months (range, 1-60).
[Table 1]. Family history: Negative 11 (13.8%), malignant diseases 32 (40.0%), cardiac diseases 18 (22.5%), epilepsy 6 (7.5%), allergic diseases 5 (6.3%), kidney diseases 5 (6.3%), and no data 3 (3.8%).
[Figure 3], (d) Overall survival according to localization of distant metastases.
[Table 3]. Transcutaneous + intracavitary brachytherapy (76.3%).